1. Home
  2. TERN vs ENGN Comparison

TERN vs ENGN Comparison

Compare TERN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TERN
  • ENGN
  • Stock Information
  • Founded
  • TERN 2017
  • ENGN 1999
  • Country
  • TERN United States
  • ENGN Canada
  • Employees
  • TERN N/A
  • ENGN N/A
  • Industry
  • TERN Biotechnology: Pharmaceutical Preparations
  • ENGN
  • Sector
  • TERN Health Care
  • ENGN
  • Exchange
  • TERN Nasdaq
  • ENGN Nasdaq
  • Market Cap
  • TERN 298.1M
  • ENGN 297.7M
  • IPO Year
  • TERN 2021
  • ENGN N/A
  • Fundamental
  • Price
  • TERN $2.71
  • ENGN $3.99
  • Analyst Decision
  • TERN Buy
  • ENGN Buy
  • Analyst Count
  • TERN 5
  • ENGN 9
  • Target Price
  • TERN $18.38
  • ENGN $25.22
  • AVG Volume (30 Days)
  • TERN 1.3M
  • ENGN 42.8K
  • Earning Date
  • TERN 05-12-2025
  • ENGN 06-13-2025
  • Dividend Yield
  • TERN N/A
  • ENGN N/A
  • EPS Growth
  • TERN N/A
  • ENGN N/A
  • EPS
  • TERN N/A
  • ENGN N/A
  • Revenue
  • TERN N/A
  • ENGN N/A
  • Revenue This Year
  • TERN N/A
  • ENGN N/A
  • Revenue Next Year
  • TERN N/A
  • ENGN N/A
  • P/E Ratio
  • TERN N/A
  • ENGN N/A
  • Revenue Growth
  • TERN N/A
  • ENGN N/A
  • 52 Week Low
  • TERN $1.87
  • ENGN $3.50
  • 52 Week High
  • TERN $11.40
  • ENGN $16.62
  • Technical
  • Relative Strength Index (RSI)
  • TERN 49.80
  • ENGN 33.10
  • Support Level
  • TERN $2.22
  • ENGN $3.77
  • Resistance Level
  • TERN $2.43
  • ENGN $4.19
  • Average True Range (ATR)
  • TERN 0.26
  • ENGN 0.41
  • MACD
  • TERN 0.08
  • ENGN 0.02
  • Stochastic Oscillator
  • TERN 83.25
  • ENGN 37.69

About TERN Terns Pharmaceuticals Inc.

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: